Package Leaflet: Information for the User
Memantine Hydrochloride 10 mg Film-Coated Tablets EFG
Hidrocloruroof memantine
Read this leaflet carefully before you start to take this medicine because it contains important information for you.
Memantina Alter contains the active ingredient hydrochloride of memantine. It belongs to a group of medications known as dementia medications.
The memory loss in Alzheimer's disease is due to an alteration in brain signals. The brain contains called N-methyl-D-aspartate (NMDA) receptors that participate in the transmission of important nervous signals in learning and memory.
Memantine belongs to the group of medications called NMDA receptor antagonists. Memantine acts on these receptors by improving the transmission of nervous signals and memory.
Memantina Alter is used in the treatment of patients with moderate to severe Alzheimer's disease.
Do not take Memantina Alter
Warnings and precautions
Consult your doctor or pharmacist before starting to take Memantina Alter:
In the above situations, treatment must be closely monitored and your doctor should regularly reevaluate the clinical benefit of memantine.
If you have kidney problems (renal insufficiency), your doctor should closely monitor your renal function and, if necessary, adjust the memantine dosage.
If you have renal tubular acidosis (ATR, excess of acid-producing substances in the blood due to renal dysfunction) or severe urinary tract infections, your doctor may need to adjust the medication dosage.
Memantine should be avoided when used with other medications such as amantadine (for Parkinson's treatment), ketamine (a general anesthetic), dextromethorphan (a cough medication), and other NMDA antagonists.
Children and adolescents
Memantina Alter is not recommended for use in children and adolescents under 18 years old.
Taking Memantina Alter with other medications
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Specifically, the administration of Memantina Alter may produce changes in the effects of the following medications, so your doctor may need to adjust the dosages:
If you are admitted to a hospital, inform your doctor that you are taking Memantina Alter.
Taking Memantina Alter with food and drinks
You should inform your doctor if you have recently changed or intend to change your diet significantly (for example, from a normal diet to a strict vegetarian diet), as your doctor may need to adjust the medication dosage.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy:Memantine is not recommended for use in pregnant women.
Breastfeeding:Women taking memantine should not breastfeed.
Driving and operating machinery
Your doctor will inform you if your condition allows you to drive and use machinery safely. Additionally, memantine may alter your reaction time, making driving or operating machinery inappropriate.
Memantina Alter contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is practically "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose of memantine in adult patients and elderly patients is 20 mg administered once a day. To reduce the risk of adverse effects, this dose is achieved gradually following the daily schedule below:
Week 1 | half tablet of 10 mg |
Week 2 | one tablet of 10 mg |
Week 3 | one and a half tablets of 10 mg |
Week 4 and onwards | two tablets of 10 mg once a day |
The normal starting dose is half tablet once a day (1 x 5 mg) in the first week. It is increased to one tablet a day (1 x 10 mg) in the second week and to one and a half tablets a day in the third week. From the fourth week onwards, the normal dose is two tablets administered once a day (1 x 20 mg).
Dosage for patients with renal insufficiency
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should monitor your renal function periodically.
Administration
Memantine Alter should be administered orally once a day. To get the most out of your medication, you should take it every day and at the same time. The tablets should be swallowed with a little water. The tablets can be taken with or without food.
Treatment duration
Continue taking Memantine Alter as long as it is beneficial for you. Your doctor should evaluate the effects of your treatment periodically.
If you take more Memantine Alter than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Memantine Alter
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Adverse effects are generally classified as mild to moderate.
Frequent (affects between 1 and 10 of every 100 patients):
Poorly frequent (affects between 1 and 10 of every 1,000 patients):
Very rare (affects fewer than 1 of every 10,000 patients):
Unknown frequency (frequency cannot be estimated from available data):
Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use website:www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
If you consider any of the adverse effects you are experiencing to be severe or if you notice any adverse effect not mentioned in this prospectus, inform your doctor or pharmacist.
Keepthismedicationout of the reach of children.
This medication does not require special conditions for conservation.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
Do not dispose of medications through drains or trash. Dispose of packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Memantina Alter
The active ingredient ishydrochlorideof memantine. Each film-coated tablet contains 10 mg ofhydrochlorideof memantine,which is equivalent to 8.31 mg of memantine.
The other components are Microcrystalline cellulose, Povidone K-25, Sodium croscarmellose, Magnesium stearate, Hydroxypropyl cellulose, and Talc.
Appearance of the product and contents of the packaging
Memantina Alter 10 mg are film-coated tablets of white color, oblong shape, biconvex, and with a breaking line.
The tablet can be divided into two equal halves.
Blister formed by PVC+PCTFE+PVC and Aluminum. The blister packs contain 56 and 112 tablets.
Other presentations:
Memantina Alter 20 mg film-coated tablets EFG
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Laboratorios Alter S.A.
Mateo Inurria, 30
28036 Madrid
Responsible for manufacturing
Laboratorio Alter, S.A.
C/ Mateo Inurria 30
28036 Madrid
Spain
Last review of this leaflet:December2023
The detailed and updated information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.